News

JIC Venture Growth Investments has acquired the shares in Linqmed Inc. (Linqmed), through its JIC Venture Growth Fund 2.

‍

Liqmed was founded in 2022 with the vision of “Link for life : Connecting science and medicine”  and aims to establish “Visible” cancer treatments(Theranotics*) using the copper radioisotope(64Cu**) for both cancer diagnosis and treatment. Based on the National institute of Quantum Science and Technology(QST)., Linqmed has built own radiopharmaceuticals and provide a drug discovery pipeline and platform business targeting cancers.

‍

The purpose of VGI’s investment is to contribute to the realization of a healthy and long-lived society by providing innovative treatments to Japanese patients through social implementation of new modalities based on Japanese technology. On top of that, VGI also aims to strengthen the startup ecosystem by encouraging Japanese entrepreneurs.

‍

VGI would like to support Linqmed to accelerate the research and development and contribute to the revitalization of the venture ecosystem.

‍

_{*Theranotics is the new medical technology that integrates treatment and diagnosis which attracts global attention due to the accelerating speed of drug development, etc.}

_{** 64Cu is a radioactive isotope of copper with a half-life of about 12-13 hours.}

‍

_{The information contained in this notice is current at the time of publication and subject to change without notice.}